Literature DB >> 8127576

Postnatal retinal vascularization in former preterm infants with retinopathy of prematurity.

H A Mintz-Hittner1, F L Kretzer.   

Abstract

PURPOSE: To study the postnatally vascularized retina in former preterm infants in whom retinopathy of prematurity (ROP) stages 2 to 4a developed and spontaneously regressed.
METHODS: Matched fundus photographs and fluorescein angiograms of the temporal peripheral retinas of 133 eyes (72 patients) were obtained after 2 years of age (mean, 7.7 years; range, 2-16.2 years) and were quantified by two masked observers with respect to the following parameters: (1) macular ectopia (in disc diameters); (2) vessel traction (in 30 degrees sectors); (3) radial length of postnatally vascularized retina (in disc diameters); and (4) capillary scaffolding of postnatally vascularized retina (as a density). These cicatricial outcomes were then compared with their active worst ROP stage.
RESULTS: Of the 133 retinal montages, the following active worst ROP stages had been documented: 30 with stage 2, 42 with stage 3 mild, 32 with stage 3 moderate, 20 with stage 3 severe, and 9 with stage 4a. As active worst ROP stage increased, macular ectopia and vessel traction increased, and radial length and capillary scaffolding of postnatal retinal vascularization decreased. Retinal holes were documented frequently in eyes with high myopia.
CONCLUSIONS: The peripheral retina in former preterm infants warrants close scrutiny for possible late rhegmatogenous retinal detachments. Prolonged retinal traction (by remnant shunt and extraretinal fibrovascular proliferation) between stable, posterior, prenatally vascularized retina, and unstable, postnatally vascularized retina may lead to the development of retinal holes characteristically located in the fragile, anterior, undifferentiated, nonvascularized retina.

Entities:  

Mesh:

Year:  1994        PMID: 8127576     DOI: 10.1016/s0161-6420(94)31301-7

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  8 in total

1.  Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.

Authors:  Helen A Mintz-Hittner; Megan M Geloneck; Alice Z Chuang
Journal:  Ophthalmology       Date:  2016-05-27       Impact factor: 12.079

2.  Fluorescein Angiography in Retinopathy of Prematurity: Comparison of Infants Treated with Bevacizumab to Those with Spontaneous Regression.

Authors:  Sasha A Mansukhani; Amy K Hutchinson; Rebecca Neustein; Joseph Schertzer; John C Allen; G Baker Hubbard
Journal:  Ophthalmol Retina       Date:  2019-01-31

3.  Idiopathic maculopathy in eyes with regressed retinopathy of prematurity.

Authors:  Kyoung Min Lee; Jeong Hun Kim; Young Suk Yu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-03-23       Impact factor: 3.117

4.  Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.

Authors:  Helen A Mintz-Hittner; Kathleen A Kennedy; Alice Z Chuang
Journal:  N Engl J Med       Date:  2011-02-17       Impact factor: 91.245

5.  Angiographic findings in cases with a history of severe retinopathy of prematurity treated with anti-VEGFs: Follow-up to age 6 years.

Authors:  Hande Celiker; Ozlem Sahin
Journal:  Int Ophthalmol       Date:  2021-11-02       Impact factor: 2.031

6.  Reply: Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.

Authors:  Helen A Mintz-Hittner
Journal:  Retina       Date:  2009-04       Impact factor: 4.256

Review 7.  Review of effects of anti-VEGF treatment on refractive error.

Authors:  Helen A Mintz-Hittner; Megan M Geloneck
Journal:  Eye Brain       Date:  2016-06-15

8.  Evaluation of Treatment Models in the Treatment of Retinopathy of Prematurity.

Authors:  Semra Tiryaki Demir; Dilek Güven; Murat Karapapak; Hasan Sinan Uslu; Ali Bülbül; İbrahim Çağrı Türker; Selam Yekta Şendül; Burcu Dirim
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2019-08-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.